The Institute for Clinical and Economic Review may soon join a key Medicaid commission in recommending the US consider a new way of pricing and reimbursing drugs granted accelerated approval where prices would be set low to account for the unproven clinical benefit, then rise as new confirmatory evidence becomes available.
ICER is coming out with a white paper on the accelerated approval pathway on Monday, 26 April and questions and comments from President Steve Pearson on 16 April at ICER’s Midwest Comparative Effectiveness Public Advisory Council (CEPAC) policy roundtable
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?